Isosorbide Esters for Atopic Dermatitis Barrier Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for skin conditions such as ichthyosis vulgaris and atopic dermatitis fail to address the underlying issue of skin barrier dysfunction, leading to impaired keratinocyte differentiation and increased susceptibility to allergens and inflammation.
Innovation Solution
The use of novel esters of isosorbide, specifically C16 to C20 mono- and di-esters, which modulate genetic networks and cellular pathways to improve skin barrier function, repair epidermal injury, and enhance stratum corneum development, thereby addressing defects in filaggrin and SASPase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for skin conditions, then symptomatic relief may be achieved, but the underlying skin barrier dysfunction is not addressed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of isosorbide esters to specific chain lengths (C16-C20) and saturation levels to optimize their ability to modulate genetic networks and cellular pathways, thereby improving skin barrier function and keratinocyte differentiation
Solution Approach 2:
The patent uses composite materials by combining isosorbide with specific fatty acid chains (C16-C20 mono- and di-esters) to create a composite ester structure that exhibits enhanced biological activity in modulating skin barrier function and gene expression compared to simpler structures
2Object-affected harmful factors
If the skin barrier is compromised, then susceptibility to allergens and inflammation increases, but current treatments do not repair the barrier
Solution Approach 1:
The patent applies preliminary action by using isosorbide esters to proactively modulate genetic networks and cellular pathways before allergen exposure or inflammation occurs, preventing barrier dysfunction rather than merely treating symptoms after they manifest
Solution Approach 2:
The patent implements feedback mechanisms by demonstrating that isosorbide esters upregulate filaggrin and SASPase, which in turn strengthen the skin barrier and reduce allergen penetration, creating a positive feedback loop that continuously improves barrier function and reduces susceptibility
3Reliability
If filaggrin and SASPase activity is reduced, then skin barrier development is impaired, but conventional therapies do not address this root cause
Solution Approach 1:
The patent applies parameter changes by optimizing the fatty acid chain parameters (length C16-C20, saturation level) of isosorbide esters to achieve maximum upregulation of filaggrin and SASPase gene expression and enzymatic activity, thereby improving stratum corneum development
Solution Approach 2:
The patent uses isosorbide esters as intermediary molecules that mediate between external application and internal genetic network modulation, acting as a bridge to upregulate filaggrin and SASPase expression without directly manipulating DNA or complex genetic pathways
Data Source
AI summary
A method of improving skin health and condition comprising the application of select isohexides to the skin.